Life Molecular Imaging had secured fast-track designation from the U.S. Food and Drug Administration (FDA) for its new PET radiotracer for visualizing brain tau pathology associated with neurodegenerative diseases.
F-18 PI-2620 is currently in phase III clinical development for detecting tau pathology in Alzheimer's disease and is being investigated in other neurodegenerative diseases, Life Molecular said. Tau proteins are a hallmark of several neurodegenerative disorders including Alzheimer’s disease, progressive supranuclear palsy, corticobasal degeneration, and frontotemporal lobar dementia.
The ability to accurately image tau pathology could significantly enhance disease diagnosis and patient care, the company said.
![Pittsburgh Compound B (PiB) PET distribution volume ratio (DVR) images were projected onto fsaverage surfaces from FreeSurfer and surface smoothed, with PiB (amyloid) slope maps created using ordinary least squares regression (time as only factor) and mixed effects models for 154 participants run at each vertex (P < .01; model: longitudinal Geriatric Depression Scale score estimated by amyloid slope × time + [sex + education + age] × time). This map visualizes the results of the linear mixed-effects models (t score of the main variable, amyloid slope × time) such that regions with a greater t score (red) represent areas in which greater depressive symptoms are associated with greater amyloid accumulation (amyloid slope). Anatomical landmarks are provided: L refers to the left hemisphere, R refers to the right hemisphere, and additional labels indicate the anterior and posterior ends of the brain. Images available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of JAMA Open Network.](https://img.auntminnie.com/files/base/smg/all/image/2024/08/PET_depression.66cf997f7e441.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
